Nomura Holdings, Inc. · TSE:8604
Nomura — Celesio — Nomura Healthcare Conference 2012
17 slides from Nomura's conference presentation, Jun 28, 2012
Slide 1: Celesio Nomura Healthcare Conference
Celesio Nomura Healthcare Conference London, 28 June 2012 1
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements. In addition to statements which are forward-looking by reason of context, forward-looking statements are indicated by the use of words such as “expect”, “intend”, “plan”, “predict”, “assume”, “believe”, “estimate”, “may”, “shall”,
Slide 3: 2011 in review
2011 • Difficult markets in Europe • Consequences of the financial crisis • Increased competition • Celesio • Impairments • Forecast achieved: EUR 578m EBITDA (before one-offs) • New strategy developed • Acquisition of Oncoprod • Operational Excellence Program (OEP) started 3
Slide 4: FY 2011 – Group Key Figures
FY 2011 – Group Key Figures • Group revenue slightly decreased • EBITDA significantly reduced by EUR 120 m • EPS at 0,01 Cent due to weak EBITDA and impairments 1) 2011 adjusted for non-recurring effects (including tax effect) primarily in connection with the Operational Excellence Program. 2) 2011
Slide 5: Strategic realignment
Strategic realignment • Focus on core business • European pharmacy network • Regional expansion • Review Manufacturer Solutions • Operational Excellence Program 5
Slide 6: Operational Excellence Program
Operational Excellence Program • Building an international procurement • Strengthening market position in Sweden • Optimizing of logistics network • Reducing of administration costs 6
Slide 7: International Procurement on track
International Procurement on track • Feasibility study completed in 2011 • Control system already installed • 9 European contracts for generics already signed • 8 contracts for goods not for resale agreed • 5 additional contracts presently negotiated 7
Slide 8: Financial overview
Financial overview celesio
Slide 9: Q1 2012 – Restructuring on track
Q1 2012 – Restructuring on track • EBITDA above prior-year level at EUR 139.9m (plus 5.1 per cent) • Operational Excellence Program showing first results • Sales process of Movianto, Pharmexx and DocMorris mail-order pharmacy initiated 9
Slide 10: Q1 2012 – Group Key Figures
Q1 2012 – Group Key Figures • Group revenues increased by 2.5% despite austerity measures • Positive EBITDA development especially in UK and Germany 1) 2011 adjusted for non-recurring effects (including tax effect) primarily in connection with the Operational Excellence Program. 2) 2011 adjusted for
Slide 11: Q1 2012 – Patient and Consumer Solutions
Q1 2012 – Patient and Consumer Solutions • Revenue increased in almost all countries • Very strong development in UK, Sweden and Norway • EBITDA increased due to Operational Excellence Program 1) Adjusted for non-recurring effects (including tax effect) primarily in connection with the Operational E
Slide 12: Q1 2012 – Pharmacy Solutions
Q1 2012 – Pharmacy Solutions • Revenues increase by 1.8% mainly due to the strong development in Germany and Denmark as well as the acquisition of Oncoprod • Gross profit was also up as a result of the improved business development in Germany and the consolidation of Oncoprod • EBITDA declined due t
Slide 13: Q1 2012 – Discontinued Operations
Q1 2012 – Discontinued Operations • Revenue of the DocMorris mail-order pharmacy was up significantly – mainly due to successful marketing measures and the marketing cooperation started in the previous year • Movianto’s gross profit developed well, mainly due to new customers • Pharmexx below the pr
Slide 14: Outlook
Outlook celesio
Slide 15: Roadmap
Roadmap 2014: Growth • Roll out EPN and E-2-E • Regional expansion possible • Full effect from OEP 2013: Realignment • Pilot phase of European Pharmacy Network (EPN) • Pilot phase of End-to-end supply chain (E-2-E) 2012: Stabilization • Stabilizing earnings (FY 2012e: > 578 Mio. €) • Implementation
Slide 16: Outlook 2012
Outlook 2012 • EBITDA guidance confirmed • Operational Excellence Program ahead of plan • Patient and Consumer Solutions showing strong momentum • Sale of Manufacturer Solutions well on track • Strategic projects developing as planned • Oncoprod developing very well 16
Slide 17: Corporate Investor Relations
Corporate Investor Relations Celesio AG Neckartalstrasse 155 70376 Stuttgart Germany Telephone +49 (0)711.5001-735 Fax +49 (0)711.5001-740 [email protected] www.celesio.com 17